Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

1.

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial.

Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A.

Ann Oncol. 2014 Jul 25. pii: mdu237. [Epub ahead of print]

PMID:
25122671
[PubMed - as supplied by publisher]
2.

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.

Vermersch P, Benrabah R, Schmidt N, Zéphir H, Clavelou P, Vongsouthi C, Dubreuil P, Moussy A, Hermine O.

BMC Neurol. 2012 Jun 12;12:36. doi: 10.1186/1471-2377-12-36.

PMID:
22691628
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

Georgin-Lavialle S, Lhermitte L, Suarez F, Yang Y, Letard S, Hanssens K, Feger F, Renand A, Brouze C, Canioni D, Asnafi V, Chandesris MO, Aouba A, Gineste P, Macintyre E, Mansfield CD, Moussy A, Lepelletier Y, Dubreuil P, Hermine O.

Eur J Haematol. 2012 Jul;89(1):47-52. doi: 10.1111/j.1600-0609.2012.01761.x. Epub 2012 Apr 28.

PMID:
22324351
[PubMed - indexed for MEDLINE]
4.

Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.

Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, Hermine O.

PLoS One. 2011;6(10):e26375. doi: 10.1371/journal.pone.0026375. Epub 2011 Oct 21.

PMID:
22031830
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.

Cadot P, Hensel P, Bensignor E, Hadjaje C, Marignac G, Beco L, Fontaine J, Jamet JF, Georgescu G, Campbell K, Cannon A, Osborn SC, Messinger L, Gogny-Goubert M, Dubreuil P, Moussy A, Hermine O.

Vet Dermatol. 2011 Dec;22(6):554-64. doi: 10.1111/j.1365-3164.2011.00990.x. Epub 2011 Jun 13.

PMID:
21668810
[PubMed - indexed for MEDLINE]
6.

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.

Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, Dubreuil P, Moussy A, Hermine O.

Alzheimers Res Ther. 2011 Apr 19;3(2):16. doi: 10.1186/alzrt75.

PMID:
21504563
[PubMed]
Free PMC Article
7.

Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.

Thamm DH, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, Hermine O, Dubreuil P.

Vet J. 2012 Jan;191(1):131-4. doi: 10.1016/j.tvjl.2011.01.001. Epub 2011 Feb 17.

PMID:
21333567
[PubMed - indexed for MEDLINE]
8.

Safety of masitinib mesylate in healthy cats.

Daly M, Sheppard S, Cohen N, Nabity M, Moussy A, Hermine O, Wilson H.

J Vet Intern Med. 2011 Mar-Apr;25(2):297-302. doi: 10.1111/j.1939-1676.2011.0687.x. Epub 2011 Feb 11.

PMID:
21314730
[PubMed - indexed for MEDLINE]
9.

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.

Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmérini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O.

Am J Hematol. 2010 Dec;85(12):921-5. doi: 10.1002/ajh.21894.

PMID:
21108325
[PubMed - indexed for MEDLINE]
10.

Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.

Hahn KA, Legendre AM, Shaw NG, Phillips B, Ogilvie GK, Prescott DM, Atwater SW, Carreras JK, Lana SE, Ladue T, Rusk A, Kinet JP, Dubreuil P, Moussy A, Hermine O.

Am J Vet Res. 2010 Nov;71(11):1354-61. doi: 10.2460/ajvr.71.11.1354. Erratum in: Am J Vet Res. 2011 Feb;72(2):247.

PMID:
21034327
[PubMed - indexed for MEDLINE]
11.

Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.

Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, Moussy A, Kinet JP, Hermine O, Rougier P, Raymond E.

Cancer Chemother Pharmacol. 2010 Jul;66(2):395-403. doi: 10.1007/s00280-010-1299-8. Epub 2010 Apr 4.

PMID:
20364428
[PubMed - indexed for MEDLINE]
12.

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O.

Eur J Cancer. 2010 May;46(8):1344-51. doi: 10.1016/j.ejca.2010.02.014. Epub 2010 Mar 6.

PMID:
20211560
[PubMed - indexed for MEDLINE]
13.

Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.

Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A, Hermine O, Dubreuil P.

PLoS One. 2010 Mar 4;5(3):e9430. doi: 10.1371/journal.pone.0009430.

PMID:
20209107
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Drug-induced minimal change nephropathy in a dog.

Sum SO, Hensel P, Rios L, Brown S, Howerth EW, Driskell EA, Moussy A, Hermine O, Brown CA.

J Vet Intern Med. 2010 Mar-Apr;24(2):431-5. doi: 10.1111/j.1939-1676.2010.0471.x. No abstract available.

PMID:
20136717
[PubMed - indexed for MEDLINE]
15.

Masitinib for the treatment of canine atopic dermatitis: a pilot study.

Daigle J, Moussy A, Mansfield CD, Hermine O.

Vet Res Commun. 2010 Jan;34(1):51-63. doi: 10.1007/s11259-009-9332-2. Epub 2009 Dec 23.

PMID:
20033487
[PubMed - indexed for MEDLINE]
16.

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.

Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L, Georgin-Lavialle S, Cohen-Akenine A, Launay JM, Barete S, Feger F, Arock M, Catteau B, Sans B, Stalder JF, Skowron F, Thomas L, Lorette G, Plantin P, Bordigoni P, Lortholary O, de Prost Y, Moussy A, Sobol H, Dubreuil P.

J Invest Dermatol. 2010 Mar;130(3):804-15. doi: 10.1038/jid.2009.281. Epub 2009 Oct 29.

PMID:
19865100
[PubMed - indexed for MEDLINE]
Free Article
17.

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O.

PLoS One. 2009 Sep 30;4(9):e7258. doi: 10.1371/journal.pone.0007258.

PMID:
19789626
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.

Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, Tunon-de-Lara JM, Pison C, Aubier M, Charpin D, Vachier I, Purohit A, Gineste P, Bader T, Moussy A, Hermine O, Chanez P.

Allergy. 2009 Aug;64(8):1194-201. doi: 10.1111/j.1398-9995.2009.02122.x.

PMID:
19614621
[PubMed - indexed for MEDLINE]
19.

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.

Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loët X, Gineste P, Guy L, Mansfield CD, Moussy A, Dubreuil P, Hermine O, Sibilia J.

Arthritis Res Ther. 2009;11(3):R95. doi: 10.1186/ar2740. Epub 2009 Jun 23.

PMID:
19549290
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

Soria JC, Massard C, Magné N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP.

Eur J Cancer. 2009 Sep;45(13):2333-41. doi: 10.1016/j.ejca.2009.05.010. Epub 2009 Jun 21.

PMID:
19541476
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk